Topic Highlight
Copyright ©2010 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Biol Chem. May 26, 2010; 1(5): 103-108
Published online May 26, 2010. doi: 10.4331/wjbc.v1.i5.103
Role of plasma membrane calcium ATPase 2 in spinal cord pathology
Amanda Kathleen Fakira, Stella Elkabes
Amanda Kathleen Fakira, Stella Elkabes, Department of Neurology and Neuroscience, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 185 S. Orange Avenue, Newark, NJ 07003, United States
Stella Elkabes, Department of Neurological Surgery and the Tim Reynolds Family Spine Research Center, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 185 S. Orange Avenue, Newark, NJ 07003, United States
Author contributions: Fakira AK wrote the section about the distribution of PMCA2 in the CNS and prepared Figure 1; Elkabes S conceived the review and wrote the other sections.
Supported by Grants No. NS046363 from the NIH and No. 08-3073-SCR-E-0 from NJCSCR
Correspondence to: Stella Elkabes, PhD, Department of Neurology and Neuroscience, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 185 S. Orange Avenue, MSB H-590, Newark, NJ 07003, United States. elkabest@umdnj.edu
Telephone: +1-973-9722463 Fax: +1-973-9725054
Received: April 27, 2010
Revised: May 11, 2010
Accepted: May 18, 2010
Published online: May 26, 2010
Abstract

A number of studies have indicated that plasma membrane calcium ATPases (PMCAs) are expressed in the brain and spinal cord and could play important roles not only in the maintenance of cellular calcium homeostasis but also in the survival and function of central nervous system cells under pathological conditions. The different regional and cellular distributions of the various PMCA isoforms and splice variants in the nervous system and the diverse phenotypes of PMCA knockout mice support the notion that each isoform might play a distinct role. Especially in the spinal cord, the survival of neurons and, in particular, motor neurons could be dependent on PMCA2. This is indicated by the knockdown of PMCA2 in pure spinal cord neuronal cultures that leads to cell death via a decrease in collapsing response mediator protein 1 levels. Moreover, the progressive decline in the number of motor neurons in PMCA2-null mice and heterozygous mice further supports this notion. Therefore, the reported reduction in PMCA2 mRNA and protein levels in the inflamed spinal cord of mice affected by experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis, and after spinal cord contusion injury, suggests that changes in PMCA2 expression could be a cause of neuronal pathology and death during inflammation and injury. Glutamate excitotoxicity mediated via kainate receptors has been implicated in the neuropathology of both EAE and spinal cord injury, and has been identified as a trigger that reduces PMCA2 levels in pure spinal cord neuronal cultures through degradation of the pump by calpain without affecting PMCA2 transcript levels. It remains to be determined which other stimuli modulate PMCA2 mRNA expression in the aforementioned pathological conditions of the spinal cord.

Keywords: Multiple sclerosis; Spinal cord injury; Neuroprotection; Neurodegeneration; Excitotoxicity; ATP2b2; Calpain; Glia